Novo Nordisk Canada is set to introduce Awiqli® — a groundbreaking basal insulin with a once-weekly dosing schedule — in Canada on June 30, 2024. Approved by Health Canada in March 2024, Awiqli® aims to enhance glycemic control for adults with diabetes mellitus. This new treatment option derives its efficacy from the ONWARDS clinical trial program, which demonstrated its safety and effectiveness.
Awiqli® represents a significant shift from daily to weekly insulin injections, potentially improving adherence and quality of life for diabetes patients. The ONWARDS trials, which encompassed over 4,000 adults with type 1 and type 2 diabetes, confirmed the basal insulin’s ability to maintain glycemic control. Adverse reactions common to insulin treatments, such as hypoglycemia and injection site issues, were noted. Despite these potential side effects, the once-weekly administration is expected to appeal to many since it addresses the burden of daily injections.
Image Credit: Novo Nordisk Canada